γ-H2AX nuclear foci detection by immunofluorescence
Cells . | γ-H2AX-positive . | t test, P value less than . |
---|---|---|
P | 20 ± 6 | - |
B/A | 60 ± 13 | 10- 10 v P |
P + Wt/Caff | 5 ± 1 | 10- 4 v P |
B/A + Wt/Caff | 19 ± 2 | 10- 7 v B/A |
B/A + STI571 | 30 ± 6 | 10- 7 v B/A |
B/A + PDTC | 29 ± 5 | 10- 6 v B/A |
mBMC | 27 ± 8 | - |
mBMC-B/A | 61 ± 14 | 10- 6 v mBMC |
hBMC | 2 ± 1 | - |
CML | 17 ± 2 | 10- 4 v hBMC |
Cells . | γ-H2AX-positive . | t test, P value less than . |
---|---|---|
P | 20 ± 6 | - |
B/A | 60 ± 13 | 10- 10 v P |
P + Wt/Caff | 5 ± 1 | 10- 4 v P |
B/A + Wt/Caff | 19 ± 2 | 10- 7 v B/A |
B/A + STI571 | 30 ± 6 | 10- 7 v B/A |
B/A + PDTC | 29 ± 5 | 10- 6 v B/A |
mBMC | 27 ± 8 | - |
mBMC-B/A | 61 ± 14 | 10- 6 v mBMC |
hBMC | 2 ± 1 | - |
CML | 17 ± 2 | 10- 4 v hBMC |
Numbers indicate the mean percentages plus or minus standard deviation of cells with γ-H2AX foci (at least 5 foci/cell). Statistical significance (P) of the results versus other experimental groups is shown.
P indicates 32Dc13 parental cells; B/A, BCR/ABL-positive counterparts; Wt/Caff, cells treated with wortmannin + caffeine; B/A + STI571, B/A cells treated with imatinib mesylate; B/A + PDTC, B/A cells treated with PTDC; mBMC, normal murine bone marrow cells; mBMC-B/A, BCR/ABL-transformed cells; hBMC, human BMC from healthy donors; CML, human BMC from patients with CML; -, not applicable; and v, versus.